Research Progress of IDH1 Gene Mutation in Glioma
Author(s): TAN Chun-lei, SU Jun, JIN Hua, CHANG Liang, LI Guo Fu, WANG Xin, ZHANG Xue-xin, The Tumor Hospital of Harbin Medical University
Pages: 2554-2557
Year: 2015 Issue: 13
Journal: Biomagnetism
Keyword: Glioma; IDH1; Mutation;
Abstract: Glioma is the most common malignant intracranial tumor,with the increase of prevalence. Mounting evidences suggest the correlatin between IDH1 gene mutation and glioma. This article reviews the research on glioma and IDH1 gene mutation. IDH1 encodes the cytoplasmic NADP dependent isocitrate dehydrogenase1 that catalyzes the oxidative decarboxylation of isocitrate into α-ketoglutarate. IDH1 is mutated in 40 % of gliomas, with most common in secondary glioblastoma. As an important metabolic enzyme,IDH1 mutation results in a new enzymatic activity transforming α-ketoglutarate into 2-hydroxyglutarate(2-HG). The oncometabolite2-HG accumulates in the cell and acts as a competitive inhibitor of many α-ketoglutaratment of novel molecular classification and therapy.e dependent cellular reactions. Moreover, IDH1 mutation may alter the metabolism and epigenome of gliomas. Furthermore, IDH1 mutation increased angiogenesis because of accumulation of HIF-1α. IDH1 mutation is a strong and independent predictor of survival,whatever grade considered. Studies of IDH1 mutations have provided mechanistic insights into tumorigenesis and potential avenues for therapeutic intervention, and may lead to the development of novel molecular classification and therapy.
Pages: 2554-2557
Year: 2015 Issue: 13
Journal: Biomagnetism
Keyword: Glioma; IDH1; Mutation;
Abstract: Glioma is the most common malignant intracranial tumor,with the increase of prevalence. Mounting evidences suggest the correlatin between IDH1 gene mutation and glioma. This article reviews the research on glioma and IDH1 gene mutation. IDH1 encodes the cytoplasmic NADP dependent isocitrate dehydrogenase1 that catalyzes the oxidative decarboxylation of isocitrate into α-ketoglutarate. IDH1 is mutated in 40 % of gliomas, with most common in secondary glioblastoma. As an important metabolic enzyme,IDH1 mutation results in a new enzymatic activity transforming α-ketoglutarate into 2-hydroxyglutarate(2-HG). The oncometabolite2-HG accumulates in the cell and acts as a competitive inhibitor of many α-ketoglutaratment of novel molecular classification and therapy.e dependent cellular reactions. Moreover, IDH1 mutation may alter the metabolism and epigenome of gliomas. Furthermore, IDH1 mutation increased angiogenesis because of accumulation of HIF-1α. IDH1 mutation is a strong and independent predictor of survival,whatever grade considered. Studies of IDH1 mutations have provided mechanistic insights into tumorigenesis and potential avenues for therapeutic intervention, and may lead to the development of novel molecular classification and therapy.
Related Articles